Harmony Biosciences Holdings, Inc. Common Stock (HRMY) is a publicly traded Healthcare sector company. As of May 21, 2026, HRMY trades at $31.90 with a market cap of $1.73B and a P/E ratio of 12.41. HRMY moved +3.09% today. Year to date, HRMY is -14.61%; over the trailing twelve months it is -11.90%. Its 52-week range spans $25.52 to $41.61. Analyst consensus is buy with an average price target of $43.44. Rallies surfaces HRMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HRMY financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. HRMY recently traded at $31.90. Market cap is $1.73B. P/E ratio is 12.41. Revenue is $899.11M.
| Metric | Value |
|---|---|
| Price | $31.90 |
| Market Cap | $1.73B |
| P/E Ratio | 12.41 |
| EPS | $2.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.61 |
| 52-Week Low | $25.52 |
| Volume | 19 |
| Avg Volume | 0 |
| Revenue (TTM) | $899.11M |
| Net Income | $145.62M |
| Gross Margin | 76.55% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $868.45M | $158.69M | $2.76 |
| 2024 | $714.73M | $145.49M | $2.56 |
| 2023 | $582.02M | $128.85M | $2.17 |
| 2022 | $437.86M | $181.47M | $3.07 |
9 analysts cover HRMY: 0 strong buy, 5 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $43.44.